ASRS 2020: OPT-302 has made positive progress in treating diabetic macular edema.
-
Last Update: 2020-07-30
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Optthea, a clinical-phasebiotic company that is developing new treatments for progressive retinal disease, today announced that opt-302 has made positive progress in the Ib/IIa phase clinical study of patients with refractive diabetic cartimes (DME), with the latest data being presented at the 2020 American Society of Retinal Specialists (ASRS) Annual Virtual Meeting (July 24-26, 2020). !----results showed that the ratio of patients in the OPT-302 combined arpersiathatod treatment group received a size of 10 letters from the baseline to the 12th week was 27.3 percent, compared with 0 percent for the Abercipp single drug treatment group. theOPT-302 combination therapy group received 9.1 percent of patients with a letter of 15 letters from the baseline to the 12th week, compared with 0 percent for the Abersip monodrug treatment group.in addition, the proportion of patients who lost 1 letter of BCVA from the baseline to the 12th week was 9.1% in the OPT-302 combination therapy group and 23.1% in the Apersip monodrug treatment group.diabetic retinopathy is currently one of the four reasons for the general blindness of western developed countries, with the improvement of people's living standards in China, the aging of the population, the incidence of diabetic retinopathy has gradually increased, seriously affecting the patient's visual function and quality of life..
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.